CoChat
Sign Up
Cited by 373Lymphoma Diagnosis and TreatmentChronic Lymphocytic Leukemia ResearchViral-associated cancers and disorders

The DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.

Rituximab plus Lenalidomide in Advanced Untreated Follicular Lymphoma

Open access
Morschhauser, Franck, Fowler, Nathan H., Feugier, Pierre, Bouabdallah, Reda, Tilly, Hervé, Palomba, M. Lia, Fruchart, Christophe, Libby, Edward N., Casasnovas, Rene-Olivier, Flinn, Ian W., Haioun, Corinne, Maisonneuve, Hervé, Ysebaert, Loic, Bartlett, Nancy L., Bouabdallah, Kamal, Brice, Pauline, Ribrag, Vincent, Daguindau, Nicolas, Le Gouill, Steven, Pica, Gian M., Martin Garcia-Sancho, Alejandro, López-Guillermo, Armando, Larouche, Jean-François, Ando, Kiyoshi, Gomes da Silva, Maria, André, Marc, Zachée, Pierre, Sehn, Laurie H., Tobinai, Kensei, Cartron, Guillaume, Liu, David, Wang, Jianming, Xerri, Luc, Salles, Gilles A.·2018·New England Journal of Medicine
DOI 10.1056/nejmoa1805104PMC PMC11003525
Open this paper in CoChat — free accountOpen PDF

Abstract

BACKGROUND: Rituximab plus chemotherapy has been shown to be effective in patients with advanced-stage, previously untreated follicular lymphoma; nevertheless, most patients will have a relapse. Combination immunotherapy with lenalidomide and rituximab is an immunomodulatory regimen that has shown promising activity in patients with indolent B-cell non-Hodgkin's lymphoma. METHODS: We conducted this multicenter, international, phase 3 superiority trial to evaluate rituximab plus lenalidomide, as compared with rituximab plus chemotherapy, in patients with previously untreated follicular lymphoma. Patients were randomly assigned to receive one of the two regimens, followed by maintenance monotherapy with rituximab. Treatment with rituximab plus lenalidomide consisted of 18 cycles of the two drugs, followed by rituximab maintenance therapy every 8 weeks for 12 cycles (six additional doses). Treatment with rituximab plus chemotherapy consisted of the investigator's choice of one of three rituximab-based regimens, followed by maintenance monotherapy with rituximab every 8 weeks for 12 cycles. The primary end points were complete response (confirmed or unconfirmed) at 120 weeks and progression-free survival. RESULTS: A total of 1030 patients were randomly assigned to receive rituximab plus lenalidomide (513 patients) or rituximab plus chemotherapy (517 patients). The rate of confirmed or unconfirmed complete response at 120 weeks was similar in the two groups: 48% (95% confidence interval [CI], 44 to 53) in the rituximab-lenalidomide group and 53% (95% CI, 49 to 57) in the rituximab-chemotherapy group (P=0.13). The interim 3-year rate of progression-free survival was 77% (95% CI, 72 to 80) and 78% (95% CI, 74 to 82), respectively. A higher percentage of patients in the rituximab-chemotherapy group had grade 3 or 4 neutropenia (32% vs. 50%) and febrile neutropenia of any grade (2% vs. 7%), and a higher percentage of patients in the rituximab-lenalidomide group had grade 3 or 4 cutaneous reactions (7% vs. 1%). CONCLUSIONS: Among patients with previously untreated follicular lymphoma, efficacy results were similar with rituximab plus lenalidomide and rituximab plus chemotherapy (with both regimens followed by rituximab maintenance therapy). The safety profile differed in the two groups. (Funded by Celgene; RELEVANCE ClinicalTrials.gov numbers, NCT01476787 and NCT01650701 , and EudraCT number, 2011-002792-42 .).

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1056/nejmoa1805104

Cites

30 of 30 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 30 references

Research works printed but not linked: 1

  1. Fowler N. Extended dosing lenalidomide with intensified rituximab in untreated indolent NHL. Hematol Oncol 2015;33:200-201. poster.

Cited by

Sorted by citations

Items 201–300 of 373

Related

See all

Metadata

Authors
Morschhauser, F., Fowler, N. H., Feugier, P., Bouabdallah, R., Tilly, H., Palomba, M. L., Fruchart, C., Libby, E. N., Casasnovas, R.-O., Flinn, I. W., Haioun, C., Maisonneuve, H., Ysebaert, L., Bartlett, N. L., Bouabdallah, K., Brice, P., Ribrag, V., Daguindau, N., Le Gouill, S., Pica, G. M., Martin Garcia-Sancho, A., López-Guillermo, A., Larouche, J.-F., Ando, K., Gomes da Silva, M., André, M., Zachée, P., Sehn, L. H., Tobinai, K., Cartron, G., Liu, D., Wang, J., Xerri, L., & Salles, G. A.
Affiliations
  • Centre National de la Recherche Scientifique (FR)
  • From Université Lille, Centre Hospitalier Universitaire (CHU), Groupe de Recherche sur les formes Injectables et les Technologies Associées, Lille (F.M.), CHU Régional de Nancy, Service d’Hématologie, Vandoeuvre lès Nancy (P.F.), Institut Paoli-Calmettes (R.B.) and Department of Pathology, Institut Paoli-Calmettes, Centre de Recherche en Cancerologie de Marseille, INSERM, Centre National de la Recherche Scientifique, Aix-Marseille Université (L.X.), Marseille, Centre Henri Becquerel, Unité 1245 and...
ORCID
Venue
New England Journal of Medicine
Publisher
Massachusetts Medical Society
Published
2018-09-06
Volume
379
Issue
10
Pages
934-947
ISSN
  • 0028-4793 (ISSN-L)
  • 1533-4406
DOI
10.1056/nejmoa1805104
PMC
PMC11003525
OpenAlex
W2891543930
Cited by
373
References
30
Citations by year
2026: 17 · 2025: 52 · 2024: 38 · 2023: 37 · 2022: 52 · 2021: 62 · 2020: 58 · 2019: 51 · 2018: 5
FWCI
33.44
Type
journal article
Language
en
Open access
Licence
www.nejmgroup.org/legal/terms-of-use.htm (vor)
Locations
  • New England Journal of Medicine (publishedVersion)
  • PubMed (publishedVersion)
  • PubMed Central (acceptedVersion)
  • Digital Commons@Becker (Washington University School of Medicine) (submittedVersion)
  • HAL (submittedVersion)
  • Archivio istituzionale della ricerca (Alma Mater Studiorum Università di Bologna) (submittedVersion)
  • DIAL (Catholic University of Leuven) (submittedVersion)
Funders
Celgene
Topics
  • Health Sciences › Medicine › Pathology and Forensic Medicine › Lymphoma Diagnosis and Treatment
  • Health Sciences › Medicine › Hematology › Chronic Lymphocytic Leukemia Research
  • Health Sciences › Medicine › Oncology › Viral-associated cancers and disorders
Keywords
follicular lymphoma, rituximab, lenalidomide, previously untreated lymphoma, rituximab plus chemotherapy, maintenance therapy, complete response, progression-free survival, neutropenia, skin reactions, immunomodulatory therapy, B-cell non-Hodgkin lymphoma, safety and tolerability
MeSH terms
Rituximab, Lenalidomide, Adult, Aged, Aged, 80 and over, Antineoplastic Combined Chemotherapy Protocols, Female, Humans, Lymphoma, Follicular, Male, Middle Aged, Neutropenia, Skin Diseases, Thalidomide, Survival Rate, Disease-Free Survival, Intention to Treat Analysis

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review